Katz DA - Search Results

1

Frequency of the frame-shifting CYP2D7 138delT polymorphism in a large, ethnically diverse sample population.

Bhathena A, Mueller T, Grimm DR, Idler K, Tsurutani A, Spear BB, Katz DA. Bhathena A, et al. Among authors: katz da. Drug Metab Dispos. 2007 Aug;35(8):1251-3. doi: 10.1124/dmd.107.014993. Epub 2007 May 9. Drug Metab Dispos. 2007. PMID: 17494644

2

Overview of pharmacogenetics.

Katz DA, Bhathena A. Katz DA, et al. Curr Protoc Hum Genet. 2009 Jan;Chapter 9:Unit 9.19. doi: 10.1002/0471142905.hg0919s60. Curr Protoc Hum Genet. 2009. PMID: 19170034 Review.

3

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.

Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA, Spear BB, Katz DA. Furman KD, et al. Among authors: katz da. Pharmacogenetics. 2004 May;14(5):279-84. doi: 10.1097/00008571-200405000-00002. Pharmacogenetics. 2004. PMID: 15115913

4

Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.

Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB. Katz DA, et al. Clin Pharmacol Ther. 2006 Mar;79(3):186-96. doi: 10.1016/j.clpt.2005.11.003. Epub 2006 Feb 17. Clin Pharmacol Ther. 2006. PMID: 16513443

5

Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy.

Katz DA, Murray B, Bhathena A, Sahelijo L. Katz DA, et al. Nat Rev Drug Discov. 2008 Apr;7(4):293-305. doi: 10.1038/nrd2486. Nat Rev Drug Discov. 2008. PMID: 18382463

6

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.

Katz DA, Grimm DR, Cassar SC, Gentile MC, Ye X, Rieser MJ, Gordon EF, Polzin JE, Gustavson LE, Driscoll RM, O'dea RF, Williams LA, Bukofzer S. Katz DA, et al. Clin Pharmacol Ther. 2004 Jun;75(6):516-28. doi: 10.1016/j.clpt.2004.01.013. Clin Pharmacol Ther. 2004. PMID: 15179406 Clinical Trial.

7

Prediction of successful weight reduction under sibutramine therapy.

Sahelijo L, Katz DA, Spear BB. Sahelijo L, et al. Among authors: katz da. Pharmacogenetics. 2004 Jun;14(6):387; author reply 387-9. doi: 10.1097/00008571-200406000-00008. Pharmacogenetics. 2004. PMID: 15247631 No abstract available.

8

Pharmacogenetics: an opportunity for codevelopment of pharmaceuticals and diagnostics.

Katz DA, Van Hove LM, Spear B. Katz DA, et al. Expert Rev Mol Diagn. 2002 Jul;2(4):291-4. doi: 10.1586/14737159.2.4.291. Expert Rev Mol Diagn. 2002. PMID: 12138484 No abstract available.

9

Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.

Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S. Graff-Guerrero A, et al. Among authors: katz da. Int J Neuropsychopharmacol. 2010 Apr;13(3):273-87. doi: 10.1017/S1461145709990642. Epub 2009 Sep 15. Int J Neuropsychopharmacol. 2010. PMID: 19751545 Free article. Clinical Trial.

10

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Innocenti F, Ramírez J, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A. Innocenti F, et al. Among authors: katz da. Pharmacogenet Genomics. 2013 Jul;23(7):374-81. doi: 10.1097/FPC.0b013e3283623e81. Pharmacogenet Genomics. 2013. PMID: 23670235 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

332 results

Search Page

Filters